The goal of this clinical trial is to determine whether the extra-virgin olive oil (EVOO) phenolic dietary supplement can improve memory function and modulate biomarkers among individuals with mild cognitive impairment (MCI). The main questions it aims to answer are: * Does dietary supplementation with EVOO phenolics improve cognitive function? * What would be the effect of the EVOO dietary supplement on other MCI-related biomarkers, including vascular function and biological pathways? Researchers will compare the EVOO dietary supplements with a placebo (a look-alike substance that contains no EVOO phenolics) Participants will: * Take EVOO dietary supplements or a placebo daily for 6 months * Visit the study site during the 6-month study for screening and testing.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Enrollment
20
EVOO phenolic dietary supplement which is standardized to contain10 mg of EVOO total phenolics
Placebo
Georgia prevention institute
Augusta, Georgia, United States
Cerebrovascular function
To assess the effect of extra virgin olive oil (EVOO) phenolic dietary supplements on blood barin barrier function using Dynamic Contrast-Enhanced MRI (DCE-MRI)
Time frame: At baseline and end of treatment (6 months)
Cerebrovascular blood flow
To assess the effect of extra virgin olive oil (EVOO) phenolic dietary supplements on cerebrovascular blood flow using Near Infrared Spectroscopy.
Time frame: At baseline and end of treament (6 months)
Cognitive function
To assess the effect of extra virgin olive oil (EVOO) phenolic dietary supplements on cognitive function, the Clinical Dementia Rating (CDR) and the National Institutes of Health (NIH) Toolbox Cognition Battery will be used. CDR and NIH Toolbox cognitive tests will be combined to report the overall effect of the intervention on changes in cognitive function. A CDR score of 0.5 indicates mild cognitive impairment, and a score of 3 indicates dementia. Those with a CDR score of 0 indicate normal cognitive function. For the NIH Toolbox tests, the Total Cognition Composite score is used, with 70 or lower indicating impaired cognition and 130 and above indicating superior cognitive ability.
Time frame: At baseline and end of treament (6 months)
Blood biomarkers
Assess concentrations of Aβ40, Aβ42, tau, and p-tau181 using highly sensitive commercially available ELISA kits. All these biomarkers will be assessed in concentration units of ng/ml, where their decrease could indicate efficacy.
Time frame: At baseline and end of treatmnet (6 months)
Proteomics
To assess the effect of extra virgin olive oil (EVOO) phenolic dietary supplements on changes in blood proteins linked to pathways associated with Alzheimer's disease.
Time frame: At baseline and end of treatmnet (6 months)
Metabolomics
To assess the effect of extra virgin olive oil (EVOO) phenolic dietary supplements on changes in blood metabolites and lipids linked to pathways associated with Alzheimer's disease.
Time frame: At baseline and end of treatment (6 months)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.